Keeping Up With CDK 4/6 Therapy in HR-Positive, HER2-Negative Advanced Breast Cancer
True or False:
Gastrointestinal toxicities associated with CDK 4/6 inhibitors are the most frequent grade 3/4 adverse event reported in clinical trials evaluating patients with advanced HR-positive, HER2-negative breast cancer.
False. Neutropenia is the most frequent grade 3/4 adverse event reported in the clinical trials of available CDK 4/6 inhibitors. It is observed to a lesser extent with abemaciclib than with palbociclib and ribociclib. For more information on adverse events associated with CDK 4/6 inhibitors, start the accredited CME activity on this page. (Sammons SL, et al. Curr Cancer Drug Targets. 2017;17:637-49; Spring LM, et al. Oncologist. 2017;22:1039-48.)
Kimberly Blackwell, MD
Professor of Medicine
Assistant Professor in Radiation Oncology
Member of the Duke Cancer Institute
Department of Medicine
Duke University School of Medicine
Sara Hurvitz, MD
Director, Breast Oncology Program
Co-Director, Santa Monica–UCLA Outpatient Oncology Practice
Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Medical Director, Clinical Research Unit
UCLA Jonsson Comprehensive Cancer Center
Santa Monica, CA
Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research
Baylor University Medical Center
The US Oncology Network
Amy Burdette, PhD
Manager, Educational Strategy & Content
Laura Rafferty, ELS
Kathryn Schaefer, MSN, RN
Lead Nurse Planner
East Lansing, MI
Mary C. Love, MA
Upon completion, participants should be able to:
- Describe the benefits and limitations of available CDK 4/6 inhibitors
- Apply clinical trial data to individualize treatment of patients with HR-positive, HER2-negative advanced breast cancer
- Evaluate toxicity profiles associated with approved CDK 4/6 inhibitors
This activity is intended for community-based oncologists.
Series Overview/Statement of Need
Advances in our understanding of the intersection between cell cycle dysregulation and cancer progression have led to the development of therapies that inhibit cyclin-dependent kinase 4/6. Three small-molecule inhibitors have received United States Food and Drug Administration approval for the treatment of individuals with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Although treatment guidelines have started to incorporate recommendations on the use of these agents, many practical questions remain regarding optimal treatment selection, appropriate patient selection, and effective sequencing of therapies.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medium/Method of Participation
This CME activity consists of a 1.0-credit publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Review Date: March 12, 2018
Initial Release Date: December 21, 2017
Expiration Date: December 20, 2018
Estimated Time to Complete This Activity: 1 hour
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Kimberly Blackwell, MD
Consulting fees/advisory boards: Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Sara Hurvitz, MD
Contracted research: Amgen, Bayer HealthCare Pharmaceuticals, BioMarin, Boehringer Ingelheim Pharmaceuticals, Inc., Cascadian Therapeutics, Dignitana, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, GlaxoSmithKline, Medivation, Inc., Merrimack Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, OBI Pharma, Inc., Pfizer, Inc., Puma Biotechnology, Inc., Seattle Genetics
Joyce O’Shaughnessy, MD
Consulting fees/advisory boards: AstraZeneca, Celgene Corporation, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For CME-related questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Google Chrome - latest version
Apple Safari - latest version
Adobe Acrobat Reader® or Adobe Reader
Adobe Flash Player
Adobe Flash Player 9 or later
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: http://www.med-iq.com/privacy-statement/.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
© 2017 Med-IQ, LLC
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.